摘要
目的:探讨亚胺培南西司他丁治疗老年肺部感染的疗效与药动学参数变化情况。方法:选取2014年4月—2016年5月濮阳市人民医院收治的老年肺部感染患者84例作为研究对象。根据入院先后顺序分为观察组和对照组,每组各42例。对照组患者给予头孢哌酮钠舒巴坦钠,观察组患者给予亚胺培南西司他丁。观察2组患者的临床疗效、细菌清除率、不良反应发生率,并分析亚胺培南西司他丁药动学参数变化情况。结果:观察组患者的总有效率为95.24%(40/42),明显高于对照组的76.19%(32/42),差异有统计学意义(P<0.05);观察组患者的细菌清除率明显高于对照组,差异有统计学意义(P<0.05);2组患者不良反应发生率的差异无统计学意义(P>0.05)。亚胺培南西司他丁的峰值浓度为(27.35±0.68)mg/L,半衰期约为1.0 h。结论:亚胺培南西司他丁治疗老年肺部感染的疗效显著,安全性较高,且药物在肺部组织中浓度较高,半衰期较短。
OBJECTIVE：To probe into the efficacy of imipenem cilastatin in treatment of elderly pulmonary infection and the changes of pharmacokinetics parameters. METHODS： 84 elderly patients with pulmonary infection admitted into Puyang People＇s Hospital from Apr. 2014 to May 2016 were selected to be divided divided into observation group and control group via the visiting sequence, with 42 cases in each. The control group were treated with cefoperazone sodium and sulbactam sodium, while the observation group received imipenem cilastatin. The clinical efficacy, bacterial clearance rate, incidence of adverse drug reactions of two groups were observed. And changes of imipenem and cilastatin pharmacokinetics were analyzed. RESULTS： The total effective rate of observation group was 95.24% （40/42）, significantly higher than that of control group [ 76. 19% （32/42）], with statistically significant difference （ P 〈 0. 05 ）. The bacterial clearance rate of observation group was significantly higher than that of control group, with statistically significant difference（P 〈 0. 05 ）. There was no statistical significance between two groups in the incidence of adverse drug reactions（P 〉 0. 05）. The peak concentration of imipenem cilastatin was （27.35±0. 68） mg/L, the half-life was about 1.0 h. CONCLUSIONS： The efficacy of imipenem cilastatin in treatment of elderly pulmonary infection is remarkable with high safety, and the drug concentration in lung tissue is high with short half-life.
出处
《中国医院用药评价与分析》
2017年第1期52-54,共3页
Evaluation and Analysis of Drug-use in Hospitals of China
关键词
亚胺培南西司他丁
老年肺部感染
药动学
Imipenem cilastatin
Elderly pulmonary infection
Pharmacokinetics
